Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Pick a track — progress rings update as you complete lessons.
23 lessons
9mNAD+ is essential to cells. That does not make every NAD+ treatment effective. A practical guide to IV claims, oral precursors and what human studies actually measured.
9mRetatrutide is Lilly's investigational GIP, GLP-1 and glucagon receptor agonist. Understand the trial findings, how it differs from approved medicines, and why it is not available by prescription.
8mPT-141 is the research name for bremelanotide, FDA-approved in 2019 as Vyleesi for low sexual desire in premenopausal women. Here's how it works, what the trials and label say about side effects, who it isn't approved for, and why research-grade PT-141 isn't the same product.
9mTirzepatide is the dual GIP/GLP-1 receptor agonist behind Mounjaro (type 2 diabetes) and Zepbound (weight management, sleep apnea). Here's what it is, what the trials showed, how it compares with semaglutide and retatrutide, and how to get evaluated by a licensed clinician.
6mARA-290 (cibinetide) explained: the EPO-derived peptide studied for small fiber neuropathy, what Phase 2 trials found, side effects, and FDA status.
7mTwo of Lilly's next obesity drugs work in completely different ways. Here's how eloralintide (amylin) and retatrutide (triple agonist) compare on the published data.
9mPhase 3 data on retatrutide side effects, in plain English: how often nausea, diarrhea, dysesthesia (skin burning), low blood pressure and injection-site reactions showed up by dose, and what the trials don't tell you.
9mGLP-1s can change sleep and mood in both directions. The pattern usually comes down to dose timing, appetite changes, side effects, and the bigger metabolic picture.
8mCagrilintide is the amylin half of CagriSema. Here's the dosing map people actually search — 2.4 mg weekly combo context, monotherapy signal, and how not to cross-titrate with eloralintide.
7mAmylin agonists can feel GLP-1-like in the gut. Here's how to think about eloralintide tolerability, escalation, and symptom tracking without turning trial data into fear content.
7mMonthly conjugates can pack a bigger post-dose GI window. Here's how to think about MariTide tolerability using Phase 2 lessons — without fear content.
8mRetatrutide's hype is not just about weight loss. The bigger story is the way a triple agonist can feel different, from warmth and energy expenditure to the GI side effects that shape adherence.
9mClinical trials show the headline results. Real-world data shows what happens after the first prescription, after the side effects, and after people try to stay on therapy long enough to benefit.
8mGLP-1 receptor agonists cause nausea in up to 44% of users and it is the top reason for discontinuation. Here is what the research shows about BPC-157 as a potential gut protectant, and where the evidence stops.
8mAOD-9604 is a synthetic fragment of human growth hormone designed specifically to stimulate fat breakdown without the glucose or IGF-1 side effects of full HGH. Here's how it works and who it's for.
8mA Stanford AI tool screened 2,600 uncharacterized peptides and identified BRP — a 12-amino acid molecule that cuts food intake by up to 50%, promotes fat burning, and avoids the nausea, constipation, and muscle loss common with GLP-1 drugs. Here's what the research actually shows.
9mMOTS-c — a peptide synthesized inside your own mitochondria — is now in Phase 2a human trials for prediabetes. Early data suggests it improves insulin sensitivity and metabolic flexibility without the side effects of pharmaceutical interventions.
12mRetatrutide is Lilly's investigational GIP/GLP-1/glucagon triple agonist. This hub covers what it is, what the trials actually reported about dosing and weight loss, how vial math works, where approval stands, and links to every retatrutide guide on PeptIQ.io.
12mRetatrutide and tirzepatide dominate the peptide conversation, but they're not interchangeable. Here's what the latest clinical research reveals about their differences, efficacy, and mechanisms.
11mExplore how Semaglutide has revolutionized weight management through GLP-1 receptor agonism.
9mLearn about Melanotan 2, the peptide that stimulates melanin production for UV-free tanning effects.
8mDiscover how AOD-9604 targets fat metabolism specifically, offering a focused approach to body composition.
9mLearn about common peptide side effects, how to minimize them, and when they require attention.
Also available at /blog for legacy links.